Monoclonal Ab Flashcards
Abatacept
RA drug when TNF alpha therapies have failed
Fc region IgG1 + extra cellular domain CTLA-4. Drug binds CD80 and CD86–> prevents second signal –> T cell cannot be activated
Ipilimumab
Binds CTLA-4 on T cells. CTLA-4 usual function is to dampen T cell activation. Ipilimumab blocks CTLA-4 –> cytotoxic T cells can destroy melanoma cells
Nivolumab
Melanoma
Anti PD-1. Blocks the T suppressing effects of PD-1 so cells are more active against tumour cells
Infliximab
RA slow clinical and radiological progression
Chimeric mAb
Anti TNFalpha
Adalimumab
Fully human IgG1 mAb
Anti TNF ALPHA
Rituximab
Anti CD20
B cell lymphoma
Infliximab and ertanacept
In IBD
Anti TNF alpha by not acting on target itself but MOPPING UP endogenous TNF alpha so none left to act on receptor
Adalimumab
IBD
ANTI TNF ab (direct action)
Anakinra
IL1
Basiliximab
Renal transplant IL2 receptor inhibitor No increase in CMV or malignancy Renal cell carcinoma Melanoma
Tocilizumab, tofacitinib
Used in RA
against IL 6
Omalizumab
Humanised IgG1 ab - binds free IgE which decreases cell bound IgE, decreases mediator release, decreases allergic inflammation
More than 95% human
Mod to severe allergic asthma on ICS/LABA
IgG levels over 30 to 700
Fortnightly to monthly subcut injections
Reduce asthma exac, increase FEV1, improved sx, reduce ICS use
HETEROGENOUS RESPONSE and hard to predict
Response only lasts as long as drug
Erlotinib
EGFR inhibitor in non small cell lung Ca with mutation
Act by REVERSIBLY binding to ATP binding site of EGFR-TK
Vemurafenib
Inhibitor of BRAF/MEK/ERK pathway (only used if BRAF has V600E mutation)
Melanoma
Cetuximab
EGFR in presence of KRAS mutation
colorectal ca
